C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 116 filers reported holding C4 THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,619,682 | -41.3% | 6,247,141 | -13.2% | 0.07% | -39.2% |
| Q2 2023 | $19,798,600 | +10.3% | 7,199,491 | +26.0% | 0.12% | +7.1% |
| Q1 2023 | $17,948,306 | -47.3% | 5,716,021 | -1.0% | 0.11% | -51.1% |
| Q4 2022 | $34,076,618 | -34.5% | 5,775,698 | -2.7% | 0.23% | -36.7% |
| Q3 2022 | $52,045,000 | +21.8% | 5,934,476 | +4.7% | 0.36% | +34.1% |
| Q2 2022 | $42,727,000 | +14.5% | 5,666,658 | +268.3% | 0.27% | +46.7% |
| Q1 2022 | $37,325,000 | -10.5% | 1,538,525 | +18.8% | 0.18% | +8.2% |
| Q4 2021 | $41,714,000 | -30.4% | 1,295,462 | -3.5% | 0.17% | -30.3% |
| Q3 2021 | $59,963,000 | +14.0% | 1,342,047 | -3.4% | 0.24% | +14.6% |
| Q2 2021 | $52,578,000 | +31.0% | 1,389,489 | +28.1% | 0.21% | +18.3% |
| Q1 2021 | $40,135,000 | – | 1,085,007 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |